We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04731675
Previous Study | Return to List | Next Study

An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04731675
Recruitment Status : Active, not recruiting
First Posted : February 1, 2021
Last Update Posted : October 6, 2022
Information provided by (Responsible Party):
AmMax Bio, Inc.

Brief Summary:
AMB-051-01 is a multicenter study with an adaptive design that will enroll approximately 12 subjects with TGCT of the knee for 12 weeks of multiple-dose, open-label treatment with AMB-05X.

Condition or disease Intervention/treatment Phase
Tenosynovial Giant Cell Tumor Pigmented Villonodular Synovitis Biological: AMB-05X Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Adaptive, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
Actual Study Start Date : May 25, 2021
Actual Primary Completion Date : May 5, 2022
Estimated Study Completion Date : October 31, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: AMB-05X

Subjects will receive an injection of AMB-05X once every 2 weeks for 12 weeks (for 6 treatments total).

Based on ongoing review of the available safety, PK, PD, and efficacy data, the Sponsor may either increase or decrease the dose.

Biological: AMB-05X
A fully human monoclonal immunoglobulin (IgG2) directed against c-fms

Primary Outcome Measures :
  1. Treatment-emergent adverse events [ Time Frame: Week 12 ]
    Frequency and severity of reported treatment-emergent adverse events

  2. Tumor response based on RECIST [ Time Frame: Week 12 ]
    Proportion of subjects who achieve an overall tumor response per the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

Secondary Outcome Measures :
  1. Tumor response based on tumor volume [ Time Frame: Week 12 ]
    Proportion of subjects with overall response based on tumor volume score

  2. Mean change from Baseline in range of motion (ROM) [ Time Frame: Week 12 ]
    ROM of the joint will be assessed by qualified assessors. Measurements will be recorded in degrees. At baseline, the plane of movement with the smallest (worst) relative value will be identified; only this plane will be used for evaluating change in ROM subsequently.

  3. Mean change from Baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function score [ Time Frame: Week 12 ]
    The PROMIS Physical Function Scale will be used to assess physical function. The scale ranges from 1 ('unable to do' or 'cannot do') to 5 ('without any difficulty' or 'not at all'), where higher scores represent better outcomes.

  4. Mean change from Baseline in Worst Stiffness Numeric Rating Scale (NRS) score [ Time Frame: Week 12 ]
    The Worst Stiffness NRS is a 1-item, self-administered questionnaire assessing the "worst" stiffness within the last 24 hours. The NRS for this item ranges from 0 (no stiffness) to 10 (stiffness as bad as you can imagine).

  5. Mean change from Baseline in Worst Pain NRS score [ Time Frame: Week 12 ]
    The Worst Pain NRS is a component of the Brief Pain Inventory assessing the "worst" pain in the last 24 hours. The NRS for this item ranges from 0 (no pain) to 10 (pain as bad as you can imagine).

  6. Mean change from Baseline in the Brief Pain Inventory (BPI) score [ Time Frame: Weeks 12 ]
    Brief Pain Inventory (BPI) Short Form is a self-administered questionnaire used to evaluate the severity of a subject's pain and the impact of this pain on the subject's daily functioning. The subject is asked to rate their worst, least, average, and current pain intensity, list current treatments and their perceived effectiveness, and rate the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life on a scale from 0 to 10.

  7. EQ-5D-5L Health Assessment [ Time Frame: Week 12 ]
    EQ-5D-5L is a widely used quality of life instrument that includes questions in each of 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The choices include 5 levels of severity for each domain followed by a general health visual analogue scale (VAS).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject ≥ 18 years
  2. A confirmed diagnosis of TGCT of the knee joint
  3. Measurable disease based on RECIST v1.1
  4. Stable prescription of analgesic regimen
  5. Negative urine drug screen (UDS) at Screening and Baseline
  6. Women of childbearing potential must have a negative pregnancy test
  7. Agrees to follow contraception guidelines
  8. Adequate hematologic, hepatic, and renal function, at Screening
  9. Willing and able to complete self-assessment instruments throughout the study

Exclusion Criteria:

  1. Prior investigational drug use within 4 weeks or 5 half-lives of Baseline
  2. Previous use of therapeutics targeting CSF1 or CSF1R or oral tyrosine kinase inhibitors
  3. History of extensive knee surgery
  4. Active cancer (either currently or within 1 year before Baseline) that requires therapy (e.g., surgery, chemotherapy, or radiation therapy)
  5. Metastatic TGCT
  6. Hepatitis C virus (HCV) or hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
  7. Known active tuberculosis
  8. Significant concomitant arthropathy in the affected joint, serious illness, uncontrolled infection, or a medical or psychiatric history
  9. Women who are breastfeeding
  10. A screening Fridericia-corrected QT interval (QTcF) ≥ 450 ms (men) or ≥ 470 ms (women)
  11. MRI contraindications (e.g., pacemaker, loose metallic implants)
  12. History of hypersensitivity to any ingredient of the study drug
  13. History of drug or alcohol abuse within 3 months before the first dose of study drug
  14. Any other severe acute or chronic medical or psychiatric condition or clinically significant laboratory abnormality that may increase the risk associated with study participation/treatment or interfere with interpretation of study results and, in the Investigator's opinion, make the subject inappropriate for this study
  15. Subjects who, in the Investigator's opinion, should not participate in the study for any reason, including if there is a question about their ability to comply with study requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04731675

Layout table for location information
United States, Ohio
AmMax Bio Clinical Site
Columbus, Ohio, United States, 43201
AmMax Bio Clinical Site
Leiden, Netherlands
AmMax Bio Clinical Site
Warsaw, Poland
AmMax Bio Clinical Site
Dnipro, Ukraine
AmMax Bio Clinical Site
Kharkiv, Ukraine
AmMax Bio Clinical Site
Kyiv, Ukraine
Sponsors and Collaborators
AmMax Bio, Inc.
Layout table for investigator information
Study Chair: Dorothy Nguyen, MD AmMax Bio, Inc.
Layout table for additonal information
Responsible Party: AmMax Bio, Inc.
ClinicalTrials.gov Identifier: NCT04731675    
Other Study ID Numbers: AMB-051-01
First Posted: February 1, 2021    Key Record Dates
Last Update Posted: October 6, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AmMax Bio, Inc.:
Tenosynovial Giant Cell Tumor
Pigmented villonodular synovitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Giant Cell Tumors
Giant Cell Tumor of Tendon Sheath
Synovitis, Pigmented Villonodular
Joint Diseases
Musculoskeletal Diseases
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Muscular Diseases